MX2020007772A - Anticuerpos humanos contra hemaglutinina de influenza. - Google Patents
Anticuerpos humanos contra hemaglutinina de influenza.Info
- Publication number
- MX2020007772A MX2020007772A MX2020007772A MX2020007772A MX2020007772A MX 2020007772 A MX2020007772 A MX 2020007772A MX 2020007772 A MX2020007772 A MX 2020007772A MX 2020007772 A MX2020007772 A MX 2020007772A MX 2020007772 A MX2020007772 A MX 2020007772A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- influenza
- influenza hemagglutinin
- human antibodies
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622480P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015029 WO2019147867A1 (en) | 2018-01-26 | 2019-01-24 | Human antibodies to influenza hemagglutinin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007772A true MX2020007772A (es) | 2020-09-18 |
Family
ID=66286952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007772A MX2020007772A (es) | 2018-01-26 | 2019-01-24 | Anticuerpos humanos contra hemaglutinina de influenza. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11780907B2 (https=) |
| EP (1) | EP3743442A1 (https=) |
| JP (2) | JP7372925B2 (https=) |
| KR (1) | KR102820941B1 (https=) |
| CN (1) | CN111670195B (https=) |
| AU (1) | AU2019212480B2 (https=) |
| BR (1) | BR112020014849A2 (https=) |
| CA (1) | CA3088194A1 (https=) |
| CL (1) | CL2020001884A1 (https=) |
| CO (1) | CO2020009043A2 (https=) |
| EA (1) | EA202091563A1 (https=) |
| IL (1) | IL275884B2 (https=) |
| MA (1) | MA51681A (https=) |
| MX (1) | MX2020007772A (https=) |
| PH (1) | PH12020551051A1 (https=) |
| SG (1) | SG11202006379UA (https=) |
| WO (1) | WO2019147867A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761428A (zh) * | 2019-10-28 | 2022-07-15 | 瑞泽恩制药公司 | 抗血凝素抗体及其使用方法 |
| WO2021202235A1 (en) * | 2020-04-01 | 2021-10-07 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| JP2023551666A (ja) * | 2020-11-23 | 2023-12-12 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ａ型インフルエンザウイルスに対する抗体 |
| WO2023201306A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
| KR102835659B1 (ko) * | 2024-11-28 | 2025-07-24 | 주식회사 마크헬츠 | 인플루엔자 a형 바이러스 검출용 항체 및 이의 용도 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| AU2006247425A1 (en) * | 2005-05-16 | 2006-11-23 | Morphotek, Inc. | Regulated vectors for selection of cells exhibiting desired phenotypes |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| JP5161882B2 (ja) | 2006-09-07 | 2013-03-13 | クルセル ホランド ベー ヴェー | インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用 |
| EP1947423A1 (en) | 2007-01-16 | 2008-07-23 | Sony Deutschland Gmbh | Distance, orientation and velocity sensitive controller |
| JP5597128B2 (ja) | 2007-05-11 | 2014-10-01 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | Ｈ５トリインフルエンザの診断および監視に有用なｈ５亜型特異的結合タンパク質 |
| SG183031A1 (en) | 2007-09-13 | 2012-08-30 | Temasek Life Sciences Lab Ltd | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof |
| WO2009035412A1 (en) | 2007-09-13 | 2009-03-19 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| US8574830B2 (en) | 2008-02-05 | 2013-11-05 | Temasek Life Sciences Laboratory Limited | Binding protein and epitope-blocking ELISA for the universal detection of H5-subtype influenza viruses |
| WO2009121004A2 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| WO2010010467A2 (en) | 2008-07-25 | 2010-01-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
| WO2010074656A1 (en) | 2008-12-24 | 2010-07-01 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof |
| JP5780762B2 (ja) * | 2008-12-25 | 2015-09-16 | 国立大学法人大阪大学 | 抗ヒトインフルエンザウイルス・ヒト型抗体 |
| AU2010247530B2 (en) | 2009-05-11 | 2016-10-13 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
| CN102482345A (zh) | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| WO2011111966A2 (en) | 2010-03-08 | 2011-09-15 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
| ES2687706T3 (es) | 2010-06-17 | 2018-10-26 | Trellis Bioscience, Llc | Anticuerpos útiles en la inmunización pasiva contra la gripe |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| WO2012045001A2 (en) | 2010-09-30 | 2012-04-05 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
| DK2731967T3 (en) | 2011-07-14 | 2017-01-16 | Janssen Vaccines & Prevention Bv | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS |
| ITRM20110606A1 (it) | 2011-11-16 | 2013-05-17 | Ist Superiore Sanita | Peptidi della lattoferrina per lo uso come inibitori ad ampio spettro dellainfezione da virus della influenza. |
| JP6325451B2 (ja) | 2011-12-02 | 2018-05-16 | アイム・セラピューティクス・べー・フェー | Ａ型インフルエンザに特異的な抗体 |
| ES2686526T3 (es) | 2011-12-05 | 2018-10-18 | Trellis Bioscience, Llc | Anticuerpos útiles en la inmunización pasiva contra la influenza |
| AU2013229488B2 (en) | 2012-03-08 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| SG10201700488QA (en) * | 2012-11-13 | 2017-02-27 | Genentech Inc | Anti-hemagglutinin antibodies and methods of use |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| EP3733244A1 (en) * | 2013-10-02 | 2020-11-04 | Medlmmune, LLC | Neutralizing anti-influenza a antibodies and uses thereof |
| JP6712428B2 (ja) | 2014-02-04 | 2020-06-24 | コントラフェクト コーポレイション | インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法 |
| EA201691945A1 (ru) | 2014-03-27 | 2017-02-28 | Дженентек, Инк. | Антитела к гемагглютинину вируса гриппа типа b и способы их применения |
| CN104031118B (zh) | 2014-06-19 | 2016-04-13 | 天津大学 | 鼠多瘤病毒衣壳粒的新型亲和肽配基及其设计筛选方法 |
| TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10435462B2 (en) | 2015-03-31 | 2019-10-08 | Viro Dynamics Corporation | Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza |
| KR102668588B1 (ko) * | 2015-04-08 | 2024-05-22 | 다나-파버 캔서 인스티튜트 인크. | 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법 |
| CN113480640B (zh) | 2015-06-01 | 2024-07-30 | 免疫医疗有限责任公司 | 中和抗流感结合分子及其用途 |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2020221450A1 (en) | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies and methods for treatment of influenza a infection |
-
2019
- 2019-01-24 KR KR1020207022064A patent/KR102820941B1/ko active Active
- 2019-01-24 JP JP2020539709A patent/JP7372925B2/ja active Active
- 2019-01-24 EP EP19719656.1A patent/EP3743442A1/en active Pending
- 2019-01-24 AU AU2019212480A patent/AU2019212480B2/en active Active
- 2019-01-24 SG SG11202006379UA patent/SG11202006379UA/en unknown
- 2019-01-24 WO PCT/US2019/015029 patent/WO2019147867A1/en not_active Ceased
- 2019-01-24 US US16/964,579 patent/US11780907B2/en active Active
- 2019-01-24 MA MA051681A patent/MA51681A/fr unknown
- 2019-01-24 IL IL275884A patent/IL275884B2/en unknown
- 2019-01-24 CA CA3088194A patent/CA3088194A1/en active Pending
- 2019-01-24 EA EA202091563A patent/EA202091563A1/ru unknown
- 2019-01-24 BR BR112020014849-0A patent/BR112020014849A2/pt not_active IP Right Cessation
- 2019-01-24 CN CN201980009873.XA patent/CN111670195B/zh active Active
- 2019-01-24 MX MX2020007772A patent/MX2020007772A/es unknown
-
2020
- 2020-07-07 PH PH12020551051A patent/PH12020551051A1/en unknown
- 2020-07-17 CL CL2020001884A patent/CL2020001884A1/es unknown
- 2020-07-23 CO CONC2020/0009043A patent/CO2020009043A2/es unknown
-
2023
- 2023-02-28 JP JP2023030129A patent/JP2023060018A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019212480A1 (en) | 2020-09-10 |
| JP2023060018A (ja) | 2023-04-27 |
| US11780907B2 (en) | 2023-10-10 |
| IL275884B2 (en) | 2024-11-01 |
| CN111670195A (zh) | 2020-09-15 |
| JP2021511043A (ja) | 2021-05-06 |
| KR102820941B1 (ko) | 2025-06-16 |
| CL2020001884A1 (es) | 2020-12-11 |
| IL275884A (en) | 2020-08-31 |
| EP3743442A1 (en) | 2020-12-02 |
| KR20200115517A (ko) | 2020-10-07 |
| CA3088194A1 (en) | 2019-08-01 |
| US20210371505A1 (en) | 2021-12-02 |
| SG11202006379UA (en) | 2020-07-29 |
| PH12020551051A1 (en) | 2021-08-23 |
| AU2019212480B2 (en) | 2025-07-24 |
| MA51681A (fr) | 2021-05-05 |
| JP7372925B2 (ja) | 2023-11-01 |
| CO2020009043A2 (es) | 2020-07-31 |
| IL275884B1 (en) | 2024-07-01 |
| BR112020014849A2 (pt) | 2020-12-08 |
| WO2019147867A1 (en) | 2019-08-01 |
| WO2019147867A9 (en) | 2019-11-07 |
| CN111670195B (zh) | 2024-08-13 |
| EA202091563A1 (ru) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000498A1 (es) | Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920) | |
| MX386403B (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| CO2020009043A2 (es) | Anticuerpos humanos contra hemaglutinina de influenza | |
| CO2019000968A2 (es) | Anticuerpos anti-virus del zika y métodos de uso | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| CO2022005281A2 (es) | Anticuerpos antihemaglutinina y métodos de uso de estos | |
| MX2020007050A (es) | Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas. | |
| ECSP21039816A (es) | Anticuerpos monoclonales antirrábicos y cóctel de estos | |
| HK1238655A1 (en) | Human antibodies to influenza hemagglutinin | |
| EA201990300A1 (ru) | Антитела к вирусу зика и способы их применения | |
| EA202191973A3 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| AR104480A1 (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola |